An evaluation of sirolimus in renal transplantation

Bibliography

• Stel VS, Kramer A, Zoccali C, Jager KJ. The 2007 ERA-EDTA registry annual report-a precis. NDT Plus 2009;2:514-21
   PubMedGoogle Scholar
• US Renal Data System UADTAoCKDaE-SRDitUS NIoH. National institute of diabetes and digestive and kidney diseases. Bethesda, MD: 2009
   Google Scholar
• Sayegh MH, Carpenter CB. Transplantation 50 years later--progress, challenges, and promises. N Engl J Med 2004;351:2761-6
   PubMed Web of Science ®Google Scholar
• Nickeleit V, Hirsch HH, Zeiler M, BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000;15:324-32
   PubMed Web of Science ®Google Scholar
• Buhaescu I, Izzedine H, Covic A. Sirolimus--challenging current perspectives. Ther Drug Monit 2006;28:577-84
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Passerini P. Gastrointestinal complications in renal transplant recipients. Transpl Int 2005;18:643-50
   PubMed Web of Science ®Google Scholar
• Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009;4:2029-34
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CL, The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33
   PubMedGoogle Scholar
• Halloran PF, de Freitas DG, Einecke G, An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010;10:2223-30
   PubMed Web of Science ®Google Scholar
• Seron D, Arns W, Chapman JR. Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies. Nephrol Dial Transplant 2008;23:2467-73
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428-37
   PubMed Web of Science ®Google Scholar
• Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69:2227-43
   PubMed Web of Science ®Google Scholar
• Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807-18
   PubMed Web of Science ®Google Scholar
• Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010;23:253-62
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
   PubMed Web of Science ®Google Scholar
• Kälble T, Alcaraz A, Budde K, Immunosuppression after kidney transplantation. In: Guidelines on renal transplantation. European Association of Urology (EAU); Arnhem, The Netherlands: 2010
   Google Scholar
• Chang AT, Platt JL. The role of antibodies in transplantation. Transplant Rev (Orlando) 2009;23:191-8
   PubMedGoogle Scholar
• Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006(2):CD004290
   Google Scholar
• Cruzado JM. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev (Orlando) 2008;22:73-81
   PubMedGoogle Scholar
• Campistol JM, Eris J, Oberbauer R, Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9
   PubMed Web of Science ®Google Scholar
• Magnasco A, Rossi A, Catarsi P, Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives. Curr Clin Pharmacol 2008;3:166-73
   PubMedGoogle Scholar
• Keown PA, Stiller CR, Wallace AC. Effect of cyclosporine on the kidney. J Pediatr 1987;111:1029-33
   PubMed Web of Science ®Google Scholar
• Webster A, Woodroffe RC, Taylor RS, Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005(4):CD003961
   Google Scholar
• Gallagher M, Jardine M, Perkovic V, Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009;87:1877-83
   PubMedGoogle Scholar
• Russ G, Segoloni G, Oberbauer R, Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005;80:1204-11
   PubMed Web of Science ®Google Scholar
• Solez K, Colvin RB, Racusen LC, Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7:518-26
   PubMed Web of Science ®Google Scholar
• Oberbauer R, Segoloni G, Campistol JM, Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005;18:22-8
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000;11:1910-17
   PubMed Web of Science ®Google Scholar
• Satoh S, Tada H, Murakami M, The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc 2005;37:1751-3
   PubMed Web of Science ®Google Scholar
• Sprangers B, Kuypers DR, Vanrenterghem Y. Immunosuppression: does one regimen fit all? Transplantation 2011;92:251-61
   PubMedGoogle Scholar
• Halloran P, Mathew T, Tomlanovich S, Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009;87:795-802
   PubMed Web of Science ®Google Scholar
• Sharif A, Shabir S, Chand S, Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011;22:2107-18
   PubMed Web of Science ®Google Scholar
• Vincenti F, Ramos E, Brattstrom C, Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-7
   PubMed Web of Science ®Google Scholar
• Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13:1365-73
   PubMedGoogle Scholar
• Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004;4:655-62
   PubMedGoogle Scholar
• Dudley C, Pohanka E, Riad H, Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005;79:466-75
   PubMed Web of Science ®Google Scholar
• Grinyo JM, Cruzado JM. Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress. Am J Transplant 2009;9:2447-52
   PubMedGoogle Scholar
• Ekberg H, Grinyo J, Nashan B, Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007;7:560-70
   PubMed Web of Science ®Google Scholar
• Abramowicz D, Del Carmen Rial M, Vitko S, Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005;16:2234-40
   PubMed Web of Science ®Google Scholar
• Frimat L, Cassuto-Viguier E, Charpentier B, Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 2006;6:2725-34
   PubMed Web of Science ®Google Scholar
• Frimat L, Cassuto-Viguier E, Provot F, Long-Term impact of cyclosporin reduction with MMF treatment in chronic allograft dysfunction: Referenece study 3-year follow up. J Transplant 2010;2010: pii: 402750
   PubMedGoogle Scholar
• Moore J, Middleton L, Cockwell P, Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009;87:591-605
   PubMed Web of Science ®Google Scholar
• Matz M, Weber U, Mashreghi MF, Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant 2010;25:2159-67
   PubMed Web of Science ®Google Scholar
• Fang YH, Joo DJ, Lim BJ, AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: a preliminary report. Transplant Proc 2010;42:976-9
   PubMed Web of Science ®Google Scholar
• Quaedackers ME, Mol W, Korevaar SS, Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 2009;88:1002-9
   PubMed Web of Science ®Google Scholar
• Busque S, Leventhal J, Brennan DC, Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009;9:1936-45
   PubMed Web of Science ®Google Scholar
• Vincenti F, Blancho G, Durrbach A, Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010;21:1587-96
   PubMed Web of Science ®Google Scholar
• Durrbach A, Pestana JM, Pearson T, A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10:547-57
   PubMed Web of Science ®Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010;10:535-46
   PubMed Web of Science ®Google Scholar
• Ferguson R, Grinyo J, Vincenti F, Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66-76
   PubMed Web of Science ®Google Scholar
• Morath C, Arns W, Schwenger V, Sirolimus in renal transplantation. Nephrol Dial Transplant 2007;22(Suppl 8):viii61-viii5
   PubMedGoogle Scholar
• Guba M, Pratschke J, Hugo C, Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transpl Int 2012;25:416-23
   PubMed Web of Science ®Google Scholar
• Brennan DC, Legendre C, Patel D, Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011;11:2453-62
   PubMedGoogle Scholar
• Wali RK, Drachenberg C, Hirsch HH, BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004;78:1069-73
   PubMed Web of Science ®Google Scholar
• Benavides CA, Pollard VB, Mauiyyedi S, BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007;84:83-8
   PubMed Web of Science ®Google Scholar
• Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010;23:133-42
   PubMed Web of Science ®Google Scholar
• Suwelack B, Malyar V, Koch M, The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) 2012;26:201-11
   PubMedGoogle Scholar
• Nashan B, Gaston R, Emery V, Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012;93:1075-85
   PubMed Web of Science ®Google Scholar
• Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991;52:185-91
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-32
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84
   PubMed Web of Science ®Google Scholar
• Dantal J. Everolimus: preventing organ rejection in adult kidney transplant recipients. Expert Opin Pharmacother 2012;13:767-78
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253:905-9
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34
   PubMed Web of Science ®Google Scholar
• Wang L, Lawrence JC Jr, Sturgill TW, Harris TE. Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J Biol Chem 2009;284:14693-7
   PubMed Web of Science ®Google Scholar
• Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007;82:381-8
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995;17:660-5
   PubMedGoogle Scholar
• Kim DH, Sarbassov DD, Ali SM, mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110:163-75
   PubMed Web of Science ®Google Scholar
• Loewith R, Jacinto E, Wullschleger S, Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002;10:457-68
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29
   PubMed Web of Science ®Google Scholar
• Cao W, Manicassamy S, Tang H, Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008;9:1157-64
   PubMed Web of Science ®Google Scholar
• Sinclair LV, Finlay D, Feijoo C, Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 2008;9:513-21
   PubMed Web of Science ®Google Scholar
• Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008;205:565-74
   PubMed Web of Science ®Google Scholar
• Araki K, Turner AP, Shaffer VO, mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-12
   PubMed Web of Science ®Google Scholar
• Geissler EK, Schlitt HJ. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 2010;78:1075-9
   PubMed Web of Science ®Google Scholar
• Heidt S, Roelen DL, Eijsink C, Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 2008;86:1292-300
   PubMed Web of Science ®Google Scholar
• Weichhart T, Saemann MD. Sirolimus and kidney transplantation: unraveling an inflammatory affair. Am J Transplant 2010;10:2569-70
   PubMedGoogle Scholar
• Saemann MD, Haidinger M, Hecking M, The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009;9:2655-61
   PubMed Web of Science ®Google Scholar
• Bohler T, Waiser J, Lichter S, Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. Cytokine 2008;42:306-11
   PubMedGoogle Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30
   PubMed Web of Science ®Google Scholar
• Bissler JJ, McCormack FX, Young LR, Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-51
   PubMed Web of Science ®Google Scholar
• Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010;30:1044-56
   PubMed Web of Science ®Google Scholar
• Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011;23:744-55
   PubMed Web of Science ®Google Scholar
• Schonenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011;26:18-24
   PubMed Web of Science ®Google Scholar
• Novalic Z, van der Wal AM, Leonhard WN, Dose-Dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 2012;23:842-53
   PubMed Web of Science ®Google Scholar
• Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011;79:502-11
   PubMed Web of Science ®Google Scholar
• Hartmann B, Schmid G, Graeb C, Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int 2005;68:2593-8
   PubMedGoogle Scholar
• Budde K, Glander P. Pharmacokinetic principles of immunosuppressive drugs. Ann Transplant 2008;13:5-10
   PubMed Web of Science ®Google Scholar
• Leogrande D, Teutonico A, Ranieri E, Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis 2007;50:314-25
   PubMedGoogle Scholar
• Di Paolo S, Teutonico A, Ranieri E, Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am J Kidney Dis 2007;49:462-70
   PubMedGoogle Scholar
• Kelly PA, Napoli K, Kahan BD. Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. Biopharm Drug Dispos 1999;20:249-53
   PubMed Web of Science ®Google Scholar
• Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001;23:559-86
   PubMed Web of Science ®Google Scholar
• Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001;40:573-85
   PubMed Web of Science ®Google Scholar
• Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999;39:1155-61
   PubMed Web of Science ®Google Scholar
• Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48-53
   PubMed Web of Science ®Google Scholar
• Podder H, Stepkowski SM, Napoli KL, Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001;12:1059-71
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Merlini S, Zenoni S, Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005;5:2937-44
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Pallet N, Rabant M, Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006;70:1019-25
   PubMed Web of Science ®Google Scholar
• Klawitter J, Gottschalk S, Hainz C, Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol 2010;23:608-19
   PubMed Web of Science ®Google Scholar
• Gottschalk S, Cummins CL, Leibfritz D, Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology 2011;32:50-7
   PubMed Web of Science ®Google Scholar
• Klawitter J, Kushner E, Jonscher K, Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res 2010;9:865-75
   PubMed Web of Science ®Google Scholar
• Schmitz V, Klawitter J, Bendrick-Peart J, Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron Exp Nephrol 2009;111:e80-91
   Google Scholar
• Klawitter J, Bendrick-Peart J, Rudolph B, Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol 2009;22:118-28
   PubMed Web of Science ®Google Scholar
• Zimmerman JJ, Lasseter KC, Lim HK, Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J Clin Pharmacol 2005;45:1368-72
   PubMed Web of Science ®Google Scholar
• Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 1998;31:345-51
   PubMed Web of Science ®Google Scholar
• Yatscoff R, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation 1993;56:1202-6
   PubMed Web of Science ®Google Scholar
• Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996;49:209-16
   PubMed Web of Science ®Google Scholar
• Kahan BD, Julian BA, Pescovitz MD, Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999;68:1526-32
   PubMed Web of Science ®Google Scholar
• Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202
   PubMed Web of Science ®Google Scholar
• MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-80
   PubMed Web of Science ®Google Scholar
• Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003;35:37S-51S
   Google Scholar
• McAlister VC, Gao Z, Peltekian K, Sirolimus-tacrolimus combination immunosuppression. Lancet 2000;355:376-7
   PubMed Web of Science ®Google Scholar
• Gonwa T, Mendez R, Yang HC, Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003;75:1213-20
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004;77:252-8
   PubMed Web of Science ®Google Scholar
• van Hooff JP, Squifflet JP, Wlodarczyk Z, A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003;75:1934-9
   PubMed Web of Science ®Google Scholar
• Woodle ES, Vincenti F, Lorber MI, A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 2005;5:157-66
   PubMed Web of Science ®Google Scholar
• Van Gurp E, Bustamante J, Franco A, Comparable renal function at 6 months with Tacrolimus combined with fixed-dose Sirolimus or MMF: results of a randomized multicenter trial in renal transplantation. J Transplant 2010;2010:pii: 731426
   Google Scholar
• Anil Kumar MS, Heifets M, Fyfe B, Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005;80:807-14
   PubMedGoogle Scholar
• Matas AJ, Granger D, Kaufman DB, Steroid minimization for sirolimus-treated renal transplant recipients. Clin Transplant 2011;25:457-67
   PubMedGoogle Scholar
• Meier-Kriesche HU, Schold JD, Srinivas TR, Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005;5:2273-80
   PubMed Web of Science ®Google Scholar
• Cohen D. A regimen of Sirolimus and reduced-dose Cyclosporine results in improved renal allograft function: combined analysis of the U.S. AND European Sirolimus-Cyclosporine trials. Am J Transplant 2004;4(Suppl 8):284; Meeting Abstract 459
   Google Scholar
• Kahan BD. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine. Transplant Proc 2008;40:S17-20
   Google Scholar
• Pliszczynski J, Kahan BD. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment. Transplant Proc 2011;43:3657-68
   PubMedGoogle Scholar
• Gaber AO, Kahan BD, Van Buren C, Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Transplantation 2008;86:1187-95
   PubMed Web of Science ®Google Scholar
• Groth CG, Backman L, Morales JM, Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-42
   PubMed Web of Science ®Google Scholar
• Kreis H, Cisterne JM, Land W, Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-60
   PubMed Web of Science ®Google Scholar
• Morales JM, Wramner L, Kreis H, Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002;2:436-42
   PubMed Web of Science ®Google Scholar
• Flechner SM, Goldfarb D, Solez K, Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007;83:883-92
   PubMed Web of Science ®Google Scholar
• Flechner SM, Goldfarb D, Modlin C, Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74:1070-6
   PubMed Web of Science ®Google Scholar
• Guerra G, Srinivas TR, Meier-Kriesche HU. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int 2007;20:813-27
   PubMedGoogle Scholar
• Pescovitz MD, Nezakatgoo N, Lorber MI, Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation 2009;88:1010-18
   PubMedGoogle Scholar
• Lo A, Egidi MF, Gaber LW, Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004;77:1228-35
   PubMed Web of Science ®Google Scholar
• Larson TS, Dean PG, Stegall MD, Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006;6:514-22
   PubMed Web of Science ®Google Scholar
• Hamdy AF, Bakr MA, Ghoneim MA. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol 2008;19:1225-32
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75
   PubMed Web of Science ®Google Scholar
• Ekberg H, Bernasconi C, Tedesco-Silva H, Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009;9:1876-85
   PubMed Web of Science ®Google Scholar
• Budde K. How to use mTOR inhibitors? The search goes on. Am J Transplant 2011;11:1551-2
   PubMedGoogle Scholar
• Flechner SM, Glyda M, Cockfield S, The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011;11:1633-44
   PubMed Web of Science ®Google Scholar
• Johnson RW, Kreis H, Oberbauer R, Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-86
   PubMed Web of Science ®Google Scholar
• Oberbauer R, Kreis H, Johnson RW, Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003;76:364-70
   PubMed Web of Science ®Google Scholar
• Guba M, Pratschke J, Hugo C, Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 2010;90:175-83
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Thierry A, Toupance O, Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009;9:1115-23
   PubMed Web of Science ®Google Scholar
• Weir MR, Mulgaonkar S, Chan L, Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011;79:897-907
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Thierry A, Thervet E, Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011;11:1665-75
   PubMed Web of Science ®Google Scholar
• Srinivas TR, Schold JD, Guerra G, Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007;7:586-94
   PubMed Web of Science ®Google Scholar
• Liefeldt L, Brakemeier S, Glander P, Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012;12:1192-8
   PubMed Web of Science ®Google Scholar
• Pascual J, Arns W. Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients? Am J Transplant 2012; doi: 10.1111/j.1600-6143.2012.04159.x. (Epub ahead of print)
   PubMedGoogle Scholar
• Alberu J, Pascoe MD, Campistol JM, Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011;92:303-10
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-42
   PubMed Web of Science ®Google Scholar
• Guba M, Pratschke J, Hugo C, Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation. Transpl Int 2012;25:416-23
   PubMed Web of Science ®Google Scholar
• Shamseddin MK, Gupta A. Sirolimus: not so sparing in the Spare-the-Nephron trial. Kidney Int 2011;79:1379; author reply -80
   PubMed Web of Science ®Google Scholar
• Mulay AV, Cockfield S, Stryker R, Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006;82:1153-62
   PubMed Web of Science ®Google Scholar
• Wali RK, Mohanlal V, Ramos E, Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007;7:1572-83
   PubMed Web of Science ®Google Scholar
• Diekmann F, Budde K, Oppenheimer F, Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004;4:1869-75
   PubMed Web of Science ®Google Scholar
• Stallone G, Schena A, Infante B, Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-23
   PubMed Web of Science ®Google Scholar
• Barozzi P, Bonini C, Potenza L, Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008;86:738-44
   PubMedGoogle Scholar
• Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008;8:2212-18
   PubMed Web of Science ®Google Scholar
• Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004;77:760-2
   PubMed Web of Science ®Google Scholar
• Kauffman HM, Cherikh WS, Cheng Y, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9
   PubMed Web of Science ®Google Scholar
• Campistol JM. Minimizing the risk of posttransplant malignancy. Transplantation 2009;87:S19-22
   Google Scholar
• Salgo R, Gossmann J, Schofer H, Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10:1385-93
   PubMed Web of Science ®Google Scholar
• Campbell SB, Walker R, Tai SS, Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012;12:1146-56
   PubMed Web of Science ®Google Scholar
• Harden PN, vdA JMH, Bouwes-Bavinck JN, Reduced rate of cutaneous squamous cell carcinoma in a randomised, prospective, multi-centre controlled trial of conversion to sirolimus-based immunosuppression: The RESCUE Trial. Transplant International 2011;24(Suppl s2):94-5
   Google Scholar
• Franco A, Hernandez D, Capdevilla L, De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc 2003;35:1764-6
   PubMed Web of Science ®Google Scholar
• Albertazzi V, Bonucchi D, De Amicis S, A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report. Transplant Proc 2010;42:1352-4
   PubMed Web of Science ®Google Scholar
• Oyen O, Strom EH, Midtvedt K, Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006;6:412-18
   PubMed Web of Science ®Google Scholar
• Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int 2010;78:1068-74
   PubMed Web of Science ®Google Scholar
• Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005;28:153-81
   PubMed Web of Science ®Google Scholar
• Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369-91
   PubMed Web of Science ®Google Scholar
• Diekmann F, Rovira J, Diaz-Ricart M, mTOR inhibition and erythropoiesis: microcytosis or anaemia? Nephrol Dial Transplant 2012;27:537-41
   PubMed Web of Science ®Google Scholar
• Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis and sirolimus--is iron the missing link? Nephrol Dial Transplant 2010;25:1667-75
   PubMed Web of Science ®Google Scholar
• Arns W, Budde K, Eitner F, Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations. Dtsch Med Wochenschr 2011;136:2554-9
   PubMed Web of Science ®Google Scholar
• Dean PG, Lund WJ, Larson TS, Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004;77:1555-61
   PubMed Web of Science ®Google Scholar
• Valente JF, Hricik D, Weigel K, Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003;3:1128-34
   PubMed Web of Science ®Google Scholar
• Campistol JM, Cockwell P, Diekmann F, Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 2009;22:681-7
   PubMed Web of Science ®Google Scholar
• Singer SJ, Tiernan R, Sullivan EJ. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000;343:1815-16
   PubMed Web of Science ®Google Scholar
• Champion L, Stern M, Israel-Biet D, Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006;144:505-9
   PubMed Web of Science ®Google Scholar
• Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011;13:551-8
   PubMed Web of Science ®Google Scholar
• Kahan BD, Knight R, Schoenberg L, Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003;35:25S-34S
   PubMed Web of Science ®Google Scholar
• Fritsche L, Budde K, Dragun D, Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004;4:130-1
   PubMed Web of Science ®Google Scholar
• Huyghe E, Zairi A, Nohra J, Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007;20:305-11
   PubMed Web of Science ®Google Scholar
• Rovira J, Diekmann F, Ramirez-Bajo MJ, Sirolimus-associated testicular toxicity: detrimental but reversible. Transplantation 2012;93:874-9
   PubMed Web of Science ®Google Scholar
• Braun M, Young J, Reiner CS, Ovarian toxicity from sirolimus. N Engl J Med 2012;366:1062-4
   PubMed Web of Science ®Google Scholar
• Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int 2010;23:1191-204
   PubMed Web of Science ®Google Scholar
• Fraenkel M, Ketzinel-Gilad M, Ariav Y, mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945-57
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim JE, Liu HY, Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 2008;283:708-15
   PubMed Web of Science ®Google Scholar
• Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-35
   PubMed Web of Science ®Google Scholar
• Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-18
   PubMed Web of Science ®Google Scholar
• Araki M, Flechner SM, Ismail HR, Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006;81:335-41
   PubMed Web of Science ®Google Scholar
• Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc 2009;41:S31-8
   PubMedGoogle Scholar
• Cohen D. A regimen of sirolimus and reduced-dose cyclosporine results in improved renal allograft function: combined analysis of the U.S. and European sirolimus-cyclosporine trials. Am J Transplant 2004;5(12):p. 2937-44
   Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004;77:244-51
   PubMed Web of Science ®Google Scholar
• Kamar N, Allard J, Ribes D, Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. Clin Nephrol 2005;63:80-6
   PubMed Web of Science ®Google Scholar
• Straathof-Galema L, Wetzels JF, Dijkman HB, Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006;6:429-33
   PubMed Web of Science ®Google Scholar
• Chapman JR, Rangan GK. Why do patients develop proteinuria with sirolimus? Do we have the answer? Am J Kidney Dis 2010;55:213-16
   PubMed Web of Science ®Google Scholar
• Buchler M, Caillard S, Barbier S, Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007;7:2522-31
   PubMed Web of Science ®Google Scholar
• Bumbea V, Kamar N, Ribes D, Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005;20:2517-23
   PubMed Web of Science ®Google Scholar
• Gutierrez MJ, Gonzalez E, Andres A, Morales JM. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction. Transplant Proc 2009;41:2348-50
   PubMed Web of Science ®Google Scholar
• Letavernier E. Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 2008;22:125-30
   PubMedGoogle Scholar
• Boratynska M, Banasik M, Watorek E, Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006;38:101-4
   PubMed Web of Science ®Google Scholar
• Abramowicz D, Hadaya K, Hazzan M, Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant 2008;23:3727-9
   PubMed Web of Science ®Google Scholar
• Diekmann F, Budde K, Slowinski T, Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transpl Int 2008;21:152-5
   PubMed Web of Science ®Google Scholar
• Fishbane S, Cohen DJ, Coyne DW, Posttransplant anemia: the role of sirolimus. Kidney Int 2009;76:376-82
   PubMed Web of Science ®Google Scholar
• Grinyo JM, Ekberg H, Mamelok RD, The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009;24:2269-76
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Le Meur Y, Cantarovich M, Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010;5:341-58
   PubMed Web of Science ®Google Scholar
• Le Meur Y, Borrows R, Pescovitz MD, Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando) 2011;25:58-64
   PubMedGoogle Scholar
• Duerr M, Glander P, Diekmann F, Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010;5:703-8
   PubMed Web of Science ®Google Scholar
• Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006;21:3252-7
   PubMed Web of Science ®Google Scholar
• Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet 2009;373:1235-6
   PubMed Web of Science ®Google Scholar
• Naesens M. Switching from calcineurin inhibitors to Mammalian target of rapamycin inhibitors--finally caught the right wave? Transplantation 2011;92:728-30
   PubMed Web of Science ®Google Scholar
• Euvrard S, Morelon E, Rostaing L, Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39
   PubMed Web of Science ®Google Scholar